

Andrew Armstrong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/962798/publications.pdf>

Version: 2024-02-01

253
papers

20,781
citations

31949

53
h-index

11047

137
g-index

262
all docs

262
docs citations

262
times ranked

17791
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 274-282.	2.0	11
2	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
3	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 363-365.	2.0	5
4	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	1.3	29
5	Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 807-810.	0.8	2
6	Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 520-522.	0.8	0
7	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 58-64.	2.0	4
8	Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2022, 82, 858-866.	1.2	10
9	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 762-769.	2.0	13
10	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
11	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1616-1622.	0.8	111
12	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
13	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	2.0	2
14	Reply to L. Marandino et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200337.	0.8	0
15	Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 227-238.	0.3	0
16	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
17	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. <i>European Journal of Cancer</i> , 2022, 170, 285-295.	1.3	9
18	Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. <i>Biosensors and Bioelectronics</i> , 2022, 213, 114445.	5.3	14

#	ARTICLE	IF	CITATIONS
19	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
20	A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS5101-TPS5101.	0.8	4
21	Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.. Journal of Clinical Oncology, 2022, 40, 5044-5044.	0.8	1
22	Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 4527-4527.	0.8	1
23	Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.. Journal of Clinical Oncology, 2022, 40, 5050-5050.	0.8	1
24	Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.. Journal of Clinical Oncology, 2022, 40, 5069-5069.	0.8	2
25	Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.. Journal of Clinical Oncology, 2022, 40, 5072-5072.	0.8	4
26	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	0.8	0
27	The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate, 2022, 82, 1237-1247.	1.2	2
28	Editorial summary: A paradigm shift in castration-resistant prostate cancer management. Prostate Cancer and Prostatic Diseases, 2022, 25, 601-603.	2.0	3
29	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 3979-3989.	3.2	8
30	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology, 2021, 4, 948-954.	2.6	18
31	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1271-1278.	0.4	10
32	Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network. Journal of General Internal Medicine, 2021, 36, 92-99.	1.3	10
33	Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum. Computational and Structural Biotechnology Journal, 2021, 19, 3842-3851.	1.9	18
34	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 1623-1630.	3.2	33
35	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 3317-3328.	3.2	14
36	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 786-793.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 157-157.	0.8	0
38	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research, 2021, 9, 14.	2.8	24
39	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 39-39.	0.8	6
40	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	2.3	299
41	<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
42	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2021, 19, 1040-1050.	1.5	17
43	Combination antiangiogenic tyrosine kinase inhibition and anti- PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	1.3	15
44	Liquid Biopsy: It's the Bloody Truth!. Clinical Cancer Research, 2021, 27, 2961-2963.	3.2	1
45	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	3.2	21
46	Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology, 2021, 28, 765-773.	0.5	10
47	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer, 2021, 127, 2954-2965.	2.0	21
48	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 4746-4756.	3.2	22
49	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology, 2021, 4, 543-552.	2.6	11
50	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
51	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	2
52	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 64-72.	0.1	4
53	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research, 2021, 9, 80.	2.8	16
54	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
56	Highlights in advanced prostate cancer from the 2021 Genitourinary Cancers Symposium: commentary.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 15, 20-23.	0.3	0
57	Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e15-79.e22.	0.8	21
58	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
59	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	0.8	141
60	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	3.4	18
61	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3
62	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
63	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
64	Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. <i>European Urology</i> , 2020, 78, 347-357.	0.9	75
65	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020, 126, 2935-2937.	2.0	0
66	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
67	A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). <i>Clinical Cancer Research</i> , 2020, 26, 3035-3043.	3.2	31
68	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 367-380.	2.0	22
69	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 517-526.	2.0	80
70	Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 64-75.	1.0	26
71	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. <i>Biosensors and Bioelectronics</i> , 2020, 162, 112250.	5.3	27
72	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020, 78, 603-614.	0.9	30
74	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	1.5	51
75	Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5589-TPS5589.	0.8	7
76	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	0.8	7
77	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	0.8	643
78	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
79	Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 4644-4655.	1.3	55
80	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	2.0	49
81	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	1.2	1
82	Molecular determinants for enzalutamide-induced transcription in prostate cancer. <i>Nucleic Acids Research</i> , 2019, 47, 10104-10114.	6.5	27
83	A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) A randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 428-437.	2.0	44
84	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2019, 14, e0216934.	1.1	14
85	Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1106-1116.	1.2	6
86	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 522-530.	2.0	15
87	Injuries involving the central tarsal bone in nonracing dogs: Short-term outcomes and prognostic factors. <i>Veterinary Surgery</i> , 2019, 48, 524-536.	0.5	8
88	E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms. <i>Molecular Cancer Research</i> , 2019, 17, 1391-1402.	1.5	35
89	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	0.8	267
90	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. <i>European Urology Oncology</i> , 2019, 2, 677-684.	2.6	22

#	ARTICLE	IF	CITATIONS
91	Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 588-592.	2.0	14
92	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. <i>Journal of Clinical Medicine</i> , 2019, 8, 205.	1.0	17
93	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	0.9	31
94	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	63
95	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 43-51.	3.2	177
96	Precision Medicine Approaches When Prostate Cancer Akts Up. <i>Clinical Cancer Research</i> , 2019, 25, 901-903.	3.2	6
97	Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer—Reply. <i>JAMA Oncology</i> , 2019, 5, 270.	3.4	1
98	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
99	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. , 2019, 194, 161-184.		244
100	PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).. <i>Journal of Clinical Oncology</i> , 2019, 37, 281-281.	0.8	2
101	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
102	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
103	Clinical utility of non-EpCAM based circulating tumor cell assays. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 132-142.	6.6	26
104	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
105	Platinum sensitivity in metastatic prostate cancer: does histology matter?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 92-99.	2.0	17
106	The promise of immunotherapy in genitourinary malignancies. <i>Precision Clinical Medicine</i> , 2018, 1, 97-101.	1.3	4
107	Updates in advanced prostate cancer 2018. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 449-450.	2.0	10
108	Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2018, 29, 2200-2207.	0.6	47

#	ARTICLE	IF	CITATIONS
109	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 944.	3.4	86
110	Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. <i>Small</i> , 2018, 14, e1801131.	5.2	115
111	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
112	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 419-430.	2.0	3
113	Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. <i>Biomarkers in Medicine</i> , 2018, 12, 727-736.	0.6	12
114	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	2.6	28
115	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17018-e17018.	0.8	1
116	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA5009-LBA5009.	0.8	24
117	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 221-227.	2.0	70
118	Drug development in prostate cancer: time to embrace RECIST?. <i>Lancet Oncology</i> , The, 2017, 18, 419-421.	5.1	5
119	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>Cancer</i> , 2017, 123, 2303-2311.	2.0	32
120	RECISTing the Temptation to Prematurely Stop Nivolumab. <i>European Urology</i> , 2017, 72, 377-378.	0.9	0
121	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	1.3	76
122	Exploiting <sc>DNA</sc> damage without repair: The activity of platinum chemotherapy in <sc>BRCA</sc>-mutated prostate cancers. <i>Cancer</i> , 2017, 123, 3441-3444.	2.0	5
123	Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. <i>Current Medical Research and Opinion</i> , 2017, 33, 1133-1139.	0.9	5
124	Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 418-424.	0.8	24
125	Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	4
126	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1137-e1141.	0.9	8

#	ARTICLE	IF	CITATIONS
127	Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. Journal of Urology, 2017, 198, 1324-1332.	0.2	9
128	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology, 2017, 71, 151-154.	0.9	306
129	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 1346-1357.	3.2	58
130	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate, 2017, 77, 385-395.	1.2	6
131	Reply to M.A.N. Åžendur et al and J. Michels. Journal of Clinical Oncology, 2017, 35, 123-123.	0.8	1
132	The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3175-3177.	0.8	5
133	Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5006-5006.	0.8	4
134	Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry.. Journal of Clinical Oncology, 2017, 35, 216-216.	0.8	0
135	Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.. Journal of Clinical Oncology, 2017, 35, 138-138.	0.8	0
136	Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16532-e16532.	0.8	1
137	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.. Journal of Clinical Oncology, 2017, 35, 5022-5022.	0.8	0
138	The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, e18280-e18280.	0.8	0
139	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
140	Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis. Lab on A Chip, 2016, 16, 3833-3844.	3.1	43
141	Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. Molecular and Cellular Biology, 2016, 36, 2503-2513.	1.1	88
142	Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology, 2016, 23, 1038-1041.	0.5	15
143	Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 488-489.	0.8	0
144	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2636-2643.	0.8	77

#	ARTICLE	IF	CITATIONS
145	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 378-388.	5.1	327
146	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2098-2106.	0.8	264
147	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 675-683.	0.9	70
148	Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. <i>Therapeutic Advances in Urology</i> , 2016, 8, 9-18.	0.9	24
149	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
150	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	0.8	332
151	Development of a Novel c-MET-Based CTC Detection Platform. <i>Molecular Cancer Research</i> , 2016, 14, 539-547.	1.5	37
152	Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 3.	1.8	22
153	Management of Prostate Cancer in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 113-132.	1.0	12
154	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016, 69, 980-983.	0.9	12
155	Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50507-50521.	0.8	44
156	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 320-320.	0.8	0
157	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16503-e16503.	0.8	0
158	New Treatment Options in Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 690-693.	2.3	11
159	Docetaxel for advanced prostate cancer: how early to start?. <i>Lancet Oncology</i> , The, 2015, 16, 741-742.	5.1	4
160	Making Progress on Progression in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1322-1324.	0.8	3
161	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 473-485.	0.9	24
162	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	0.9	36

#	ARTICLE	IF	CITATIONS
163	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 110.e1-110.e9.	0.8	17
164	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 191-210.	2.7	20
165	Prognostic and Predictive Biomarkers for Castration Resistant Prostate Cancer. <i>Biomarkers in Disease</i> , 2015, , 447-480.	0.0	1
166	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (<sc>mCRPC</sc>). <i>BJU International</i> , 2015, 116, 17-29.	1.3	19
167	Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch. <i>Clinical Cancer Research</i> , 2015, 21, 4505-4507.	3.2	4
168	A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 319-327.	0.9	12
169	Burden of Disease Matters When It Comes to Systemic Therapy for Prostate Cancer. <i>European Urology</i> , 2015, 67, 448-450.	0.9	2
170	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. <i>European Urology</i> , 2015, 67, 85-97.	0.9	403
171	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5000-5000.	0.8	25
172	Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5011-5011.	0.8	8
173	Enzalutamide (ENZA) in men with chemotherapy-Na ⁺ ve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5036-5036.	0.8	10
174	Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 200-200.	0.8	2
175	Carcinosarcomas: tumors in transition?. <i>Histology and Histopathology</i> , 2015, 30, 673-87.	0.5	21
176	Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1308-1316.	0.8	46
177	Radiographic progression by Prostate Cancer Working Group (<sc>PCWG</sc>)â€2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2014, 114, E25-E31.	1.3	39
178	Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T87-T103.	1.6	127
179	Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?. <i>International Journal of Urology</i> , 2014, 21, 1215-1219.	0.5	7
180	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 441-468.	2.7	59

#	ARTICLE	IF	CITATIONS
181	Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 991-997.	1.1	5
182	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	13.9	2,456
183	New Treatments for Men with Castration-resistant Prostate Cancer: Can We Move from Small Steps to Giant Leaps?. <i>European Urology</i> , 2014, 65, 300-302.	0.9	3
184	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	0.9	25
185	The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 3-6.	0.9	142
186	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 317-324.	0.9	60
187	Prostate Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 686-718.	2.3	294
188	Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 719-726.	2.3	141
189	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5002-5002.	0.8	6
190	Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5054-5054.	0.8	3
191	Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA1-LBA1.	0.8	43
192	Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer. , 2014, , 1-27.		0
193	Evolution of Clinical States and the Castration Resistant Clinical Paradigm. <i>Current Clinical Urology</i> , 2014, , 9-29.	0.0	0
194	A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 82-86.	0.8	74
195	Reply to M.A. Khattak et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 972-973.	0.8	0
196	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. <i>European Urology</i> , 2013, 63, 309-320.	0.9	42
197	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1307-1316.	5.1	205
198	Development of a method to isolate circulating tumor cells using mesenchymal-based capture. <i>Methods</i> , 2013, 64, 129-136.	1.9	37

#	ARTICLE	IF	CITATIONS
199	Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1457-1463.	0.8	11
200	A Phase II Trial of Tamsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	0.9	52
201	Novel Therapies for the Treatment of Advanced Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 109-126.	1.3	18
202	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R83-R99.	1.6	272
203	Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 25-33.	1.0	13
204	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1729-1737.	3.0	150
205	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3944-3950.	0.8	83
206	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20111-20116.	3.3	144
207	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. <i>Cancer Management and Research</i> , 2013, 5, 1.	0.9	101
208	Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5081-5081.	0.8	2
209	A phase II trial of tamsirolimus in men with castration-resistant metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 105-105.	0.8	1
210	Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6-6.	0.8	36
211	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8-LBA8.	0.8	30
212	A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2013, 31, 219-219.	0.8	1
213	Clinical phenotypes of castration-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 707-18.	0.3	9
214	Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. <i>Journal of Clinical Oncology</i> , 2012, 30, 3402-3407.	0.8	138
215	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 1187-1197.	13.9	3,847
216	The STAMPEDE trial and celecoxib: how to adapt?. <i>Lancet Oncology, The</i> , 2012, 13, 443-445.	5.1	3

#	ARTICLE	IF	CITATIONS
217	Utilization Trends at a Multidisciplinary Prostate Cancer Clinic: Initial 5-Year Experience From the Duke Prostate Center. <i>Journal of Urology</i> , 2012, 187, 103-108.	0.2	22
218	Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 607-613.	0.8	100
219	Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 363-369.	0.9	34
220	Reply to Yijun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2012;61:363-369. <i>European Urology</i> , 2012, 61, e4-e5.	0.9	0
221	Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 549-559.	0.9	159
222	Objective Evaluation of Bone Metastases in Prostate Cancer: To What End?. <i>European Urology</i> , 2012, 62, 85-87.	0.9	1
223	Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BJU International</i> , 2012, 110, E461-8.	1.3	30
224	Dasatinib combined with docetaxel for castration-resistant prostate cancer. <i>Cancer</i> , 2012, 118, 63-71.	2.0	138
225	Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4519-4519.	0.8	22
226	Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 204-204.	0.8	0
227	Prognostic, Predictive, and Surrogate Factors for Individualizing Treatment for Men with Castration-Resistant Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 292-297.	1.8	0
228	Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4022-4028.	0.8	197
229	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. <i>Cancer</i> , 2011, 117, 3963-3971.	2.0	35
230	Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. <i>Molecular Cancer Research</i> , 2011, 9, 997-1007.	1.5	586
231	Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy. <i>Asian Journal of Andrology</i> , 2011, 13, 179-180.	0.8	4
232	Therapy for Non-Clear Cell Histologies in Renal Cancer. <i>Current Clinical Pharmacology</i> , 2011, 6, 169-180.	0.2	8
233	Epithelial-mesenchymal transition in cancer progression. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 941-3.	0.3	6
234	The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 1-14; quiz 15-6.	0.3	82

#	ARTICLE	IF	CITATIONS
235	Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 203-211.	3.2	186
236	Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 108-116.	2.0	20
237	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3057-3066.	3.2	66
238	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. <i>European Journal of Cancer</i> , 2010, 46, 517-525.	1.3	118
239	Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature. <i>Oncologist</i> , 2009, 14, 816-827.	1.9	47
240	The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 88-93.	2.0	29
241	New drug development in metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 430-437.	0.8	19
242	Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. <i>Journal of the National Cancer Institute</i> , 2008, 100, 681-682.	3.0	4
243	A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6270-6276.	3.2	66
244	Clinical endpoints for drug development in prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 303-308.	0.9	15
245	Cell Signaling Modifiers in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 40-45.	1.0	7
246	NCCN Task Force Report: mTOR inhibition in solid tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6 Suppl 5, S1-20; quiz S21-2.	2.3	17
247	A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 6396-6403.	3.2	341
248	Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3965-3970.	0.8	257
249	Current standard and investigational approaches to the management of hormone-refractory prostate cancer. <i>Reviews in Urology</i> , 2007, 9 Suppl 1, S9-S19.	0.9	3
250	New drugs in prostate cancer. <i>Current Opinion in Urology</i> , 2006, 16, 138-145.	0.9	25
251	Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. <i>Current Oncology Reports</i> , 2005, 7, 220-227.	1.8	13
252	Advanced prostate cancer: the future. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 2, 42-7.	0.0	2

#	ARTICLE	IF	CITATIONS
253	Novel therapeutic approaches to advanced prostate cancer. Clinical Advances in Hematology and Oncology, 2005, 3, 271-82.	0.3	7